Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib with Chemotherapy in Extensive Stage SCLC
NCT02499770Phase 2Completed
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Jun 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of trilaciclib in small cell lung cancer (SCLC), sponsored by G1 Therapeutics, Inc.. Started Jun 2015; status: completed.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02499770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02499770.